BMEA
Biomea Fusion, Inc. · Healthcare
Insiders bought $197K of Biomea Fusion, Inc. in the last 12 months
2 insiders bought on 3 days.
BMEA over the last year
Largest buyers, last 12 months
BMEA after insider buys
3 months after each buy, from the first price a copier could get.
13 buys since 2021 with 3 months of prices.
Every filing
23 insider filings since 2021, newest first
Rainer M Erdtmann · Insider
Michael J.m. Hitchcock · Interim CEO
Rainer M Erdtmann · Insider
Michael J.m. Hitchcock · Director
Franco Valle · CFO
A2A Pharmaceuticals, Inc. · 10% owner
A2A Pharmaceuticals, Inc. · 10% owner
A2A Pharmaceuticals, Inc. · 10% owner
A2A Pharmaceuticals, Inc. · 10% owner
A2A Pharmaceuticals, Inc. · 10% owner
Bihua Chen · Director and 10% owner
Rainer M Erdtmann · President, COO and 10% owner
A2A Pharmaceuticals, Inc. · 10% owner
A2A Pharmaceuticals, Inc. · 10% owner
A2A Pharmaceuticals, Inc. · 10% owner
Franco Valle · CFO
A2A Pharmaceuticals, Inc. · 10% owner
Sotirios Stergiopoulos · Director
Rainer M Erdtmann · President, COO and 10% owner
Thomas Andrew Butler · CEO and 10% owner
Rainer M Erdtmann · President, COO and 10% owner
Thomas Andrew Butler · CEO and 10% owner
Bihua Chen · Director
About Biomea Fusion, Inc.
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.